Thursday, July 29, 2021 7:24:10 AM
Cantor Fitzgerald initiated coverage of Jaguar Health (NASDAQ:JAGX) with an “overweight” rating and price target of $5. The stock closed at $1.49 on July 6.
Jaguar Health is a commercial-stage pharmaceuticals company focused on plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with gastrointestinal distress, specifically chronic, debilitating diarrhea.
Analyst Louise Chen writes that Jaguar’s Mytesi (crofelemer) represents a pipeline in a product, providing potential benefits in multiple gastrointestinal disorders in humans and other animals, including dogs, dairy calves, foals and equine athletes. It is the only oral drug approved by the FDA under botanical guidance.
“Crofelemer’s market potential is underappreciated, in our view,” she said. “Therefore, we expect upwards earnings estimate revisions to move Jaguar shares higher.”
Ms. Chen said this could be driven by top-line Mytesi results from the investigator-initiated Phase 2 trial in cancer therapy-related diarrhea in 2021; a potential launch of Canalevia in chemotherapy-induced diarrhea in dogs in the fourth quarter of 2021 and exercise-induced diarrhea in dogs shortly afterward; and potential business development deals 2021.
Recent JAGX News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 10:00:33 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/05/2024 12:00:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 10:30:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:13:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 10:25:44 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 11/30/2023 01:10:26 PM
- FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS • PR Newswire (Canada) • 11/15/2023 02:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 10:03:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 09:03:29 PM
- FILAMENT HEALTH AND JAGUAR HEALTH JOINT VENTURE MAGDALENA BIOSCIENCES COMPLETES IMPORT OF COCA LEAF FROM PERU • PR Newswire (Canada) • 09/21/2023 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:55:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:53:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:50:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:49:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:48:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:46:36 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/14/2023 08:16:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 01:05:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/07/2023 09:27:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/03/2023 09:00:36 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM